Search

everythinglearnresearchcommunity

for

Search:↓

A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.

A 36-year-old man with androgenetic alopecia suspects copper and zinc deficiencies may be accelerating hair loss and is supplementing copper to address this. He is also monitoring blood sugar levels due to previous prediabetes concerns and plans to test for insulin resistance.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.

Clascoterone, a topical anti-androgen for hair loss, is expected to be released in late 2026 or early 2027.

Astaxanthin may cause increased hair shedding, affecting even transplanted hair and eyebrows. The user has tried various treatments for androgenic alopecia, including minoxidil, finasteride, and RU58841.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

OP is considering using KX-826 for hair loss due to side effects from other treatments like Minoxidil and finasteride. Users discuss the risks and safety of KX-826, with some suggesting caution due to its status as a research chemical.

The conversation is about the quality of RU58841 powder from Shaanxi Laon Biotech. The user is inquiring if anyone has experience with this product.

The conversation is about finding a reputable place to buy Clascoterone in the US. An alternative treatment, pyrilutamide, is suggested as a strong and official option.

The conversation discusses the use of topical peptides ahk-cu and ghk-cu for hair loss. One user reported that while these peptides made their hair look thicker and improved scalp health, they did not notice significant hair growth.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

Clascoterone cream was submitted for review to Health Canada in August 2022, with hopes of approval within 3-6 months. It may potentially enhance finasteride's effects for hair loss treatment.

Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

The conversation is about using Maxogen-X for hair loss, which contains Minoxidil, Finasteride, Azelaic Acid, ABN Complex, Retinoic Acid, Fluocinolone, and Caffeine. The user is seeking feedback on its effectiveness.

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

A Swiss product called Redensyl, which is supposed to target hair follicle stem cells and has recently been marketed in Europe. The post inquires if anyone has had any experience with the product.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

miR-205, a tiny RNA, can stimulate hair growth by softening aging hair follicle stem cells in mice. Future tests aim to see if this can work in humans.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.